Consistent with our previous work, the present results confirmed the accumulation of both innate and adaptive effector subsets in the tumor tissue when targeted with the combined vaccine and CD1d-anti-HER2 fusion protein therapy. The gene discussed is ERBB2; the disease is neoplasm.